513 related articles for article (PubMed ID: 10373067)
1. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
Gadisseur AP; Gratama JW; Lamers C; van Esser JW; Bolhuis RL; Cornelissen JJ
Bone Marrow Transplant; 1999 May; 23(10):1013-7. PubMed ID: 10373067
[TBL] [Abstract][Full Text] [Related]
2. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
[TBL] [Abstract][Full Text] [Related]
3. Activation-associated phenotype of CD3 T cells in acute graft-versus-host disease.
Paz Morante M; Briones J; Canto E; Sabzevari H; Martino R; Sierra J; Rodriguez-Sanchez JL; Vidal S
Clin Exp Immunol; 2006 Jul; 145(1):36-43. PubMed ID: 16792671
[TBL] [Abstract][Full Text] [Related]
4. CD25 expression distinguishes functionally distinct alloreactive CD4 CD134 (OX40) T-cell subsets in acute graft-versus-host disease.
Streeter PR; Zhang X; Tittle TV; Schön CN; Weinberg AD; Maziarz RT
Biol Blood Marrow Transplant; 2004 May; 10(5):298-309. PubMed ID: 15111929
[TBL] [Abstract][Full Text] [Related]
5. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
6. Regulation of OX40 gene expression in graft-versus-host disease.
Miura Y; Thoburn CJ; Bright EC; Arai S; Hess AD
Transplant Proc; 2005; 37(1):57-61. PubMed ID: 15808546
[TBL] [Abstract][Full Text] [Related]
7. A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell-depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation.
Broers AE; van der Holt B; Haze S; Braakman E; Gratama JW; Löwenberg B; Cornelissen JJ
Exp Hematol; 2005 Aug; 33(8):912-9. PubMed ID: 16038784
[TBL] [Abstract][Full Text] [Related]
8. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
9. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
[TBL] [Abstract][Full Text] [Related]
10. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.
Jones MS; Riley R; Hamilton BL; Paupe J; Perez D; Levy RB
Bone Marrow Transplant; 1994 Nov; 14(5):725-35. PubMed ID: 7889005
[TBL] [Abstract][Full Text] [Related]
11. The phenotype and reconstitution of immunoregulatory T cell subsets after T cell-depleted allogeneic and autologous bone marrow transplantation.
Sugita K; Soiffer RJ; Murray C; Schlossman SF; Ritz J; Morimoto C
Transplantation; 1994 May; 57(10):1465-73. PubMed ID: 7910987
[TBL] [Abstract][Full Text] [Related]
12. Transition of T cell receptor gamma/delta expressing double negative (CD4-/CD8-) lymphocytes after allogeneic bone marrow transplantation.
Yabe M; Yabe H; Hattori K; Hinohara T; Morimoto T; Kato S; Kusunoki A
Bone Marrow Transplant; 1994 Nov; 14(5):741-6. PubMed ID: 7889006
[TBL] [Abstract][Full Text] [Related]
13. Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease.
Ewing P; Miklos S; Olkiewicz KM; Müller G; Andreesen R; Holler E; Cooke KR; Hildebrandt GC
Exp Hematol; 2007 Jan; 35(1):155-63. PubMed ID: 17198884
[TBL] [Abstract][Full Text] [Related]
14. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
15. Immunomagnetic CD4+ and CD8+ cell depletion for patients at high risk for severe acute GVHD.
Jansen J; Hanks S; Akard LP; Thompson JM; Burns S; Chang Q; English D; Garrett P
Bone Marrow Transplant; 1996 Mar; 17(3):377-82. PubMed ID: 8704690
[TBL] [Abstract][Full Text] [Related]
16. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
[TBL] [Abstract][Full Text] [Related]
17. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary T cell repertoire in patients with graft-versus-host disease following blood and marrow transplantation.
Yurovsky VV; Cottler-Fox MH; Atamas SP; Shanholtz CB; Britt EJ; Sensenbrenner LL; White B
Am J Hematol; 2001 Jan; 66(1):1-11. PubMed ID: 11426485
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD134 (0X-40) on T cells during the first 100 days following allogeneic bone marrow transplantation as a marker for lymphocyte activation and therapy-resistant graft-versus-host disease.
Lamb LS; Abhyankar SA; Hazlett L; O'Neal W; Folk RS; Vogt S; Parrish RS; Bridges K; Henslee-Downey PJ; Gee AP
Cytometry; 1999 Oct; 38(5):238-43. PubMed ID: 10516610
[TBL] [Abstract][Full Text] [Related]
20. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.
Taraban VY; Rowley TF; O'Brien L; Chan HT; Haswell LE; Green MH; Tutt AL; Glennie MJ; Al-Shamkhani A
Eur J Immunol; 2002 Dec; 32(12):3617-27. PubMed ID: 12516549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
